AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMUTEP LTD

0.290

+0.0103.57%

Volume:1.10M

Turnover:317.41K

Market Cap:422.12M

PE:-8.82

High:0.295

Open:0.280

Low:0.280

Close:0.280

Loading ...

Overview Company News Filings

Immutep's Phase 1 Trial Shows Favorable Safety Profile of Drug Candidate for Autoimmune Disease; Shares Down 3%

MT Newswires Live

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

The Market Herald

There's more to Australian biotech than just CSL: the opportunities to watch

Immutep Reports Promising New Data in Head and Neck Cancer at Esmo Immuno-Oncology 2024

THOMSON REUTERS

Immutep Says Phase 2B Trial of Head, Neck Cancer Combination Therapy Shows 'Strong' Overall Survival; Shares Up 3%

MT Newswires Live

ASX 300 healthcare stock lifts off on promising new results

BUZZ-Australia's Immutep rises on 3-week high after initiation of phase-3 trial

Immutep Ltd -Company Expects to Enrol First Patient in Q1 of Cy2025

THOMSON REUTERS

Immutep Announces Initiation of Tacti-004 Phase Iii Trial in First Line Non-Small Cell Lung Cancer

THOMSON REUTERS

Immutep Starts Phase 3 Clinical Trial of Potential Lung Cancer Combination Therapy

MT Newswires Live

Is this ASX All Ords stock primed for a takeover offer in 2025?

Immutep to Focus on Cancer Treatment Trial in Fiscal 2025; Shares Up 5%

MT Newswires Live

Guess which small cap ASX share could rise 100%+

Immutep ADRs Climb on Positive Efti Trial Results

BRIEF-Positive Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMM.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMM.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.29,"timestamp":1741583520000,"preClose":0.28,"halted":0,"volume":1100242,"delay":0,"changeRate":0.035714,"change":0.01,"floatShares":1251930614,"shares":1455589575,"eps":-0.032898,"lyrEps":-0.035565,"pbRate":2.45,"amount":317406,"amplitude":0.053571,"volumeRatio":0.17495813934303367,"dividePrice":0,"prevYearClose":0.365,"fiveDayClose":0.305,"twentyDayClose":0.32},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1251930614,"roa":"-20.35%","roe":"-30.45%","lyrEps":-0.035565,"volumeRatio":0.17495813934303367,"shares":1455589575,"dividePrice":0,"high":0.295,"amplitude":0.053571,"preClose":0.28,"low":0.28,"week52Low":0.23,"pbRate":"2.45","psRate":"86.52","week52High":0.46,"institutionHeld":0,"latestPrice":0.29,"committee":0.479605,"eps":-0.032898,"divideRate":0,"volume":1100242,"delay":0,"ttmEps":-0.032898,"open":0.28,"prevYearClose":0.365,"prevWeekClose":0.28,"prevMonthClose":0.31,"prevQuarterClose":0.365,"fiveDayClose":0.305,"twentyDayClose":0.32,"sixtyDayClose":0.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492671131","title":"Immutep's Phase 1 Trial Shows Favorable Safety Profile of Drug Candidate for Autoimmune Disease; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492671131","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492671131?lang=en_us&edition=fundamental","pubTime":"2024-12-17 09:35","pubTimestamp":1734399325,"startTime":"0","endTime":"0","summary":"Immutep  said its first-in-human phase 1 trial showed a favorable safety profile of its lead drug candidate IMP761 being developed for various autoimmune diseases, according to a Tuesday filing with the Australian bourse.Results from the first three of a five single-dose ascending study showed no adverse events, with pharmacokinetic and pharmacodynamic relationship report slated for release in the first half of next year, the filing said.The company's shares were down nearly 3% in recent Tuesday trade.Price : $0.33, Change: $-0.01, Percent Change: -2.94%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","BK4125","LU0994945656.USD","LU0345774631.USD","BK7067","IMM.AU","LU0426412945.USD","LU0426417589.USD","LU1043141123.HKD","LU2238339852.HKD","BK7508"],"gpt_icon":0},{"id":"2492267620","title":"Immutep dips as safety test for flagship drug IMP761 shows no adverse effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2492267620","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492267620?lang=en_us&edition=fundamental","pubTime":"2024-12-17 07:27","pubTimestamp":1734391620,"startTime":"0","endTime":"0","summary":"Immutep Ltd  has reported a small-scale conceptual safety test among 49 patients using flagship drug IMP761 has seen no adverse effects.Despite this, shares were down nearly -3% after twenty minutes of Tuesday trade. The data released by Immutep does not actually relate to patients with autoimmune diseases, but rather, healthy patients on whom iMP761 is being tested.IMP761 is a LAG-3 agonist with that latter acronym referring to genes related to the human immune system. In many autoimmune conditions, the immune system goes ‘haywire’ and causes cancer – iMP761 attempts to go after one key type of immune system constituent to treat the targeted condition.Among those conditions are arthritis, diabetes, and MS; in the past, Immutep has also studied cancers. Blood cancers are predominantly autoimmune, even if underlying mechanics are different between different types of cancer.The material provided in this article is for information only and should not be treated as investment advice. Viewe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/immutep-dips-as-safety-test-for-flagship-drug-imp761-shows-no-adverse-effects-2024-12-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2491503738","title":"There's more to Australian biotech than just CSL: the opportunities to watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491503738?lang=en_us&edition=fundamental","pubTime":"2024-12-16 04:09","pubTimestamp":1734293355,"startTime":"0","endTime":"0","summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["TLX.AU","BK7067","BK4086","SGXZ23171101.USD","LU1169590202.USD","NEU.AU","SNT.AU","XKO.AU","DXB.AU","BOT.AU","SG9999004303.SGD","XJO.AU","BK7511","CSL.AU","IMM.AU","BK7007","CSL","XAO.AU","BK7096","BK7501","BK7508","LU1169589451.USD","OPT.AU","LU0728928796.USD","CVB.AU","BK7502"],"gpt_icon":0},{"id":"2490398383","title":"Immutep Reports Promising New Data in Head and Neck Cancer at Esmo Immuno-Oncology 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490398383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490398383?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:15","pubTimestamp":1734009300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUA7D3QYS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2490828377","title":"Immutep Says Phase 2B Trial of Head, Neck Cancer Combination Therapy Shows 'Strong' Overall Survival; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490828377","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490828377?lang=en_us&edition=fundamental","pubTime":"2024-12-12 11:38","pubTimestamp":1733974702,"startTime":"0","endTime":"0","summary":"Immutep  said its phase 2b trial evaluating eftilagimod alpha in combination with Keytruda for patients with head and neck squamous cell cancer showed \"strong\" overall survival, progression-free survival, and durability, according to a Thursday filing with the Australian bourse.The 12-month overall survival rate was 67%, well above historical controls, while the interim median duration of response was 9.3 months, the filing said. The median overall survival has not yet been reached.The Tacti-003 study also found the combination therapy continues to be well-tolerated, with no new safety concerns identified, the filing said.The biotechnology company's shares rose nearly 3% in afternoon trade Thursday.Price : $0.37, Change: $+0.01, Percent Change: +2.82%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0345774631.USD","LU0426417589.USD","IMM.AU","LU0426412945.USD","LU1043141123.HKD","LU0994945656.USD","BK7508","LU2238339852.HKD","BK4125","AUD","BK7067"],"gpt_icon":0},{"id":"2490843917","title":"ASX 300 healthcare stock lifts off on promising new results","url":"https://stock-news.laohu8.com/highlight/detail?id=2490843917","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490843917?lang=en_us&edition=fundamental","pubTime":"2024-12-12 08:38","pubTimestamp":1733963885,"startTime":"0","endTime":"0","summary":"S&P/ASX 300 Index  healthcare stock Immutep Ltd  is charging higher today. Shares in the clinical-stage biotech company closed yesterday trading for 35.5 cents. In earlier trade, shares were changing hands for 38.5 cents apiece, up 8.5%. After some likely profit-taking, shares are currently trading for 37.7 cents each, up 6.2%. For some context, the ASX 300 is up 0.4% at this same time.  This outperformance comes following the release of promising new clinical trial data. Here's what we know. What did the ASX 300 healthcare stock report?Investors are bidding up the ASX 300 healthcare stock after the company announced positive clinical results from Cohort B of its TACTI-003 Phase IIb trial.  The trial is evaluating the efficacy of Immutep's Efti product used in combination with Merck & Co's Pembrolizumab in difficult-to-treat head and neck cancer patients with negative PD-L1 expression.  (Quite a mouthful, I know!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/12/asx-300-healthcare-stock-lifts-off-on-promising-new-results/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IMM.AU","XKO.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2490907647","title":"BUZZ-Australia's Immutep rises on 3-week high after initiation of phase-3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490907647","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490907647?lang=en_us&edition=fundamental","pubTime":"2024-12-11 08:12","pubTimestamp":1733875951,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep rises on 3-week high after initiation of phase-3 trial** Shares of biotechnology company Immutep IMM.AX rise as much as 2.2% to A$0.348, their highest since Nov. 14** Co has announced initiation of phase-3 trial for the treatment of first-line metastatic non-small cell lung cancer ** Says trial will include over 150 clinical sites in over 25 countries** Co expects to enrol the first patient in Q1 of CY2025.** Stock has fallen 0.5% YTD, as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4N3NC00P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2490900200","title":"Immutep Ltd -Company Expects to Enrol First Patient in Q1 of Cy2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2490900200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490900200?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:00","pubTimestamp":1733835606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA1LDVCF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2490090148","title":"Immutep Announces Initiation of Tacti-004 Phase Iii Trial in First Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490090148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490090148?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:00","pubTimestamp":1733835606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUA1LDVCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2490300830","title":"Immutep Starts Phase 3 Clinical Trial of Potential Lung Cancer Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2490300830","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490300830?lang=en_us&edition=fundamental","pubTime":"2024-12-10 11:04","pubTimestamp":1733799877,"startTime":"0","endTime":"0","summary":"Immutep  started a phase 3 clinical trial evaluating a potential combination therapy for first-line metastatic non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.The Tacti-004 trial will assess the company's product candidate eftilagimod alfa in combination with US-based pharmaceutical company MSD's Keytruda therapy and chemotherapy, the filing said.The trial will compare this regimen with placebo in about 750 patients globally, the filing added. Immutep expects to enroll the first patient into this study during the first quarter of fiscal 2025.The trial will be conducted at over 150 clinical sites across more than 25 countries. Full approval to start the trial in the UK is expected soon, with additional approvals for multiple countries anticipated in the coming months.Shares of the biotechnology company fell nearly 1% in recent Tuesday trade.Price : $0.33, Change: $-0.003, Percent Change: -0.90%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","LU1043141123.HKD","IMM.AU","LU0426412945.USD","LU2238339852.HKD","AUD","LU0345774631.USD","BK7508","BK7067","BK4125","LU0426417589.USD"],"gpt_icon":0},{"id":"2489268384","title":"Is this ASX All Ords stock primed for a takeover offer in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489268384","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489268384?lang=en_us&edition=fundamental","pubTime":"2024-12-06 10:36","pubTimestamp":1733452596,"startTime":"0","endTime":"0","summary":"ASX All Ords stock Immutep Ltd  has underperformed the All Ordinaries Index  this past year. Over the last 12 months, Immutep shares have gained just under 5%. That compares to an almost 18% gain posted by the All Ords over this same period. Though that underperformance could change if the biotech company achieves further successes with its cancer treatment trials. Or, if the ASX All Ords stock becomes a takeover target in 2025. Is Immutep a likely takeover candidate for 2025?Asked which company in his portfolio could be an acquisition target, Antares Equities' portfolio manager, Andrew Hamilton,namedImmutep . Hamilton said the ASX All Ords stock's \"key asset is Efti, an immunotherapy drug with a unique mechanism of action that theoretically makes it highly synergistic with other immunotherapies as well as with chemotherapy and radiotherapy\". He noted that Efti \"has had a succession of very strong data in a number of different types of cancers including lung cancer, head and neck cance","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/06/is-this-asx-all-ords-stock-primed-for-a-takeover-offer-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IMM.AU","LU1430594728.SGD","LU0006306889.USD","LU1037948897.HKD","LU0266013472.USD","LU2468319806.SGD","LU2361044865.SGD","SG9999014567.USD","BK4534","XAO.AU","LU0070302665.USD","IE00BBT3K403.USD","LU1585245621.USD","LU1934455863.HKD","LU0058720904.USD","LU0861579265.USD","LU2361044949.HKD","BK4516","LU1291159041.SGD","LU1116320737.USD","IE00B4R5TH58.HKD","LU1989772923.USD","LU0211331839.USD","LU2361045086.USD","LU0203347892.USD","LU1057294990.SGD","LU0320765489.SGD","SG9999002232.USD","SG9999001176.SGD","LU1093756325.SGD","LU1571399168.USD","LU1066053197.SGD","LU1934455277.USD","LU1974910355.USD","IE00BN8TJ469.HKD","LU2023250504.SGD","LU0965509101.SGD","LU0208291251.USD","LU1941712264.USD","SGXZ57979304.SGD","LU1066051811.HKD","IE00BLSP4239.USD","BK4588","SG9999014559.SGD","LU0122379950.USD","IE00BLSP4452.SGD","LU1941712348.USD","MRK","LU0265550359.USD","LU2023250843.SGD"],"gpt_icon":0},{"id":"2485725134","title":"Immutep to Focus on Cancer Treatment Trial in Fiscal 2025; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485725134","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485725134?lang=en_us&edition=fundamental","pubTime":"2024-11-22 09:42","pubTimestamp":1732239739,"startTime":"0","endTime":"0","summary":"Immutep  will focus on developing its cancer treatment lead candidate eftilagmod alpha in fiscal 2025, Chair Russel Howard said at the annual general meeting, according to a Friday filing with the Australian bourse.The lead candidate will be evaluated in the phase 3 TACTI-004 trial to investigate its use in patients with first-line non-small cell lung cancer. The trial is set to start later in the year or early next year, the filing said.The biotechnology firm will also explore the use of eftilagmod alpha to treat head and neck squamous cell carcinoma and metastatic breast cancer, the filing added.The company's shares were up more than 5% in recent Friday trade.Price : $0.30, Change: $+0.02, Percent Change: +5.26%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","BK7508","LU0426412945.USD","LU0345774631.USD","LU2238339852.HKD","LU0426417589.USD","BK4125","IMM.AU","LU1043141123.HKD","AUD","BK7067"],"gpt_icon":1},{"id":"2484365779","title":"Guess which small cap ASX share could rise 100%+","url":"https://stock-news.laohu8.com/highlight/detail?id=2484365779","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484365779?lang=en_us&edition=fundamental","pubTime":"2024-11-18 06:36","pubTimestamp":1731882984,"startTime":"0","endTime":"0","summary":"Immutep Ltd  shares ended the week on a disappointing note. The small cap ASX biotechnology share fell 3% to finish the session at 33 cents. But its shares may not be trading at those levels for long if one leading broker is to be believed. What is being said about this small cap ASX share?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/18/guess-which-small-cap-asx-share-could-rise-100/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IMM.AU","BK7508","INAQU","BK7067"],"gpt_icon":0},{"id":"2483806921","title":"Immutep ADRs Climb on Positive Efti Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483806921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483806921?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:10","pubTimestamp":1731593400,"startTime":"0","endTime":"0","summary":"Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell lung cancer.The stock was up 12% at $2.10 in premarket trading. Shares had fallen 22% year-to-date when the market closed Wednesday.The biotechnology company said before the bell that mature survival data for patients treated with the combination were well above historical controls and exceeded expectations.\"We are encouraged to see Efti build upon the historical clinical outcomes from the most widely used immunotherapy-chemo combination today,\" Chief Executive Marc Voigt said.Early evaluations of an expanded cohort of trial patients are also tracking well, Voigt said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1941712264.USD","LU2089984988.USD","LU0006306889.USD","SG9999014542.SGD","IE000M9KFDE8.USD","LU0265550946.USD","BK4588","LU0965509010.AUD","LU1066051498.USD","LU0266013472.USD","IMMP","IE0002141913.USD","LU2106854487.HKD","SG9999015358.SGD","BK7067","SG9999001440.SGD","LU0070302665.USD","LU1934455194.USD","LU0234572021.USD","BK4533","LU1066051225.USD","LU0265550359.USD","LU2112291526.USD","LU0985320562.USD","BK4007","LU1989771016.USD","LU0861579265.USD","LU2361045086.USD","MRK","IE00BN8TJ469.HKD","SG9999013999.USD","LU1430594728.SGD","LU1917777945.USD","LU1093756168.USD","LU1585245621.USD","LU0211331839.USD","LU1989772923.USD","SG9999002224.SGD","LU1934455863.HKD","LU1066051811.HKD","IE00BLSP4239.USD","IE00BBT3K403.USD","IE00BSNM7G36.USD","SG9999014567.USD","LU0106261372.USD","BK7508","IE00B2B36J28.USD","IMM.AU","LU2361044865.SGD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2483447870","title":"BRIEF-Positive Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2483447870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483447870?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:19","pubTimestamp":1731590345,"startTime":"0","endTime":"0","summary":"Nov 14 (Reuters) - Immutep Ltd   :   * POSITIVE DATA FROM PHASE II TRIAL IN SOFT TISSUE SARCOMA PRESENTED AT CTOS 2024 ANNUAL MEETINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2483760870","title":"Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483760870","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483760870?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:15","pubTimestamp":1731590100,"startTime":"0","endTime":"0","summary":"Mature data in patients with a minimum follow-up of 22 months  shows excellent results, well above historical controls and exceeding expectations:. Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0%. Data from all evaluable patients to date  demonstrates significant improvement of Overall Response Rate compared to historical controls. Safety continues to be favourable with no new safety signals. INSIGHT-003, which is nearing completion of enrolment, evaluates efti with the most widely used immunotherapy-chemo combination today in a similar population to upcoming TACTI-004 Phase III trial. SYDNEY, AUSTRALIA, Nov. 14, 2024  -- Immutep Limited  , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha  in combination with KE","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-efti-shows-excellent-survival-131500096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["IMM.AU","INAQU","PFS","BK4211","BK7067","BK7508","BK7095","BK4139","BK4195","ORR.AU","IMMP","OS","BK4097"],"gpt_icon":1}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":63}]}}